logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > VILAZODONE CAS 163521-12-8

VILAZODONE CAS 163521-12-8

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 163521-12-8

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:
Appearance::
Light Yellow Solid
CAS NO::
163521-12-8
Molecular Formula::
C26H28ClN5O2
Molecular Weight::
477.98600
EINECS NO::
NA
MDL NO::
MFCD09838919
Appearance::
Light Yellow Solid
CAS NO::
163521-12-8
Molecular Formula::
C26H28ClN5O2
Molecular Weight::
477.98600
EINECS NO::
NA
MDL NO::
MFCD09838919
VILAZODONE CAS 163521-12-8

Product Description:

Product Name: VILAZODONE CAS NO: 163521-12-8


Synonyms:

5-[4-[4-(5-cyano-1-H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;

2-BenzofurancarboxaMide,5-[4-[4-(5-cyano-1-H-indol-3-yl)butyl]-1-piperazinyl]-;

Vilazodonei;Vilazodone5-[4-[4-(5-Cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide;


Chemical & Physical Properties:

Appearance: Light yellow solid

Assay :≥98.00%

Density: 1.34 g/cm3

Boiling Point: 745.1℃ at 760 mmHg

Melting Point: 203-205℃

Storage Temp.: Refrigerator


Vilazodone is a kind of serotonergic antidepressant developed by Merck KGaA Company. It is a novel compound with high affinity and selectivity for the 5-hydroxytrptamine (5-HT) transporter and 5-HT (1A) receptors. It is indicated for the treatment of major depressive disorder (MDD). It is can be used as an alternative drugs for other kind of antidepressant classes drugs that can’t be tolerated by patients. As a selective serotonin reuptake inhibitor, vilazodone can prevent the serotonin from re-entering into cell bodies, therefore making it remain longer inside the synapse. Moreover, it has a high selectivity for the serotonin-1A receptor, taking effect as a partial agonist that can simulate the production of serotonin. These effects result in increased serotonin in the synaptic cleft. This effect is related to the antidepressant effect of vilazodone in vivo. It is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.